---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000195"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:09:30.661039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%

## Summary
- Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.
- GAAP diluted EPS $0.23; non-GAAP diluted EPS $0.75, up 20% vs $0.63 prior year.
- Non-GAAP adjusted EBITDA $190.4M (30.2% of sales); operating cash flow $54.3M, FCF $26.5M.
- Raised FY2024 revenue guidance to $2.47B-$2.49B; non-GAAP EPS $2.80-$2.90.
- Growth driven by NuVasive acquisition, spine product volume, enabling technology sales.

## SEC filing metadata
- accession: 0001562762-24-000195
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/0001562762-24-000195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000195/gmed-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000195
- JSON: https://secwatch.observer/filing/0001562762-24-000195.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.